Safety profile showing any adverse events from Week 20 through to the end of the study (safety set).
| Secukinumab | |||||
|---|---|---|---|---|---|
| Adverse Events* | 25 mg n = 18, n (%) | 75 mg n = 23, n (%) | 150 mg n = 115, n (%) | 300 mg n = 60 n (%) | Total n = 216, n (%) |
| Any adverse event | 11 (61.1) | 15 (65.2) | 73 (63.5) | 41 (68.3) | 140 (64.8) |
| Infections and infestations | 6 (33.3) | 6 (26.1) | 40 (34.8) | 17 (28.3) | 69 (31.9) |
| Nasopharyngitis | 1 (5.6) | 4 (17.4) | 15 (13.0) | 8 (13.3) | 28 (13.0) |
| Pharyngitis | 0 | 0 | 1 (0.9) | 5 (8.3) | 6 (2.8) |
| Urinary tract infection | 2 (11.1) | 1 (4.3) | 5 (4.3) | 2 (3.3) | 10 (4.6) |
| Upper respiratory tract infection | 2 (11.1) | 0 | 6 (5.2) | 1 (1.7) | 9 (4.2) |
| Bronchitis | 0 | 0 | 6 (5.2) | 2 (3.3) | 8 (3.7) |
| Gastrointestinal infection | 1 (5.6) | 0 | 0 | 0 | 1 (0.5) |
| Gastrointestinal disorders | 0 | 3 (13.0) | 14 (12.2) | 5 (8.3) | 22 (10.2) |
| Musculoskeletal and connective tissue disorders | 3 (16.7) | 2 (8.7) | 24 (20.9) | 11 (18.3) | 40 (18.5) |
| Rheumatoid arthritis | 2 (11.1) | 0 | 6 (5.2) | 4 (6.7) | 12 (5.6) |
| General disorders and administration site conditions | 2 (11.1) | 1 (43.) | 4 (3.5) | 4 (6.7) | 11 (5.1) |
| Blood and lymphatic system disorders | 1 (5.6) | 3 (13.0) | 8 (7.0) | 5 (8.3) | 17 (7.9) |
| Investigations | 2 (11.1) | 1 (4.3) | 6 (5.2) | 3 (5.0) | 12 (5.6) |
| Nervous system disorders | 2 (11.1) | 1 (4.3) | 4 (3.5) | 6 (10.0) | 13 (6.0) |
| Reproductive system and breast disorders | 2 (11.1) | 0 | 0 | 0 | 2 (0.9) |
| Skin and subcutaneous tissue disorders | 0 | 2 (8.7) | 8 (7.0) | 7 (11.7) | 17 (7.9) |
↵* Listed affected system organ classes are those reported in at least 10% of patients; listed infections are those reported in at least 5% of patients.